A Multicenter Study for the Validation of ALS Biomarkers

Study Purpose:

The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.

Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.

Study Status:

Not recruiting

Disease:

Amyotrophic Lateral Sclerosis , Lou Gehrig's Disease , Primary Lateral Sclerosis , Nervous System Diseases , Hereditary Spastic Paraparesis

Study Type:

Observational

Type of Intervention:

N/A

Intervention Name:

N/A

Placebo:

N/A

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

James D. Berry, MD, MPH, Massachusetts General Hospital

Clinicaltrials.gov ID:

NCT00677768

Neals Affiliated?

Yes

Coordinating Center Contact Information

NCRI at the Massachusetts General Hospital

149 13th Street, BLDG 149, MGH East
Boston, Massachusetts, 02129 United States

Full Study Summary:

Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS.

Study Sponsor:

Massachusetts General Hospital

Participant Duration:

Up to 36 months

Estimated Enrollment:

475

Estimated Study Start Date:

04 / 30 / 2008

Estimated Study Completion Date:

11 / 01 / 2015

Posting Last Modified Date:

06 / 03 / 2016

Date Study Added to neals.org:

05 / 14 / 2008

Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS.

Minimum Age:

30 Years

Maximum Age:

80 Years

Can participants use Riluzole?

Yes

1. ALS Volunteers

Inclusion Criteria:

- Diagnosis of possible (excluding volunteers with UMN signs ONLY), probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to revised El Escorial criteria

- Disease duration of less than or equal to two years from symptom onset

- Age 30-80 years at the time of disease onset

- Ability to provide informed consent

- Ability to comply with study procedures

- Medically safe to have lumbar puncture (lumbar puncture volunteers only)

Exclusion Criteria:

- Clinical evidence of chronic liver or renal failure

- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)

- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)

2. Suspected ALS (PMND) Volunteers

Inclusion Criteria:

- Diagnosis of suspected ALS defined as presence of UMN or LMN signs alone and the diagnosis of Clinically Probably Laboratory-Supported ALS CANNOT be proven by evidence in clinical grounds in conjunction with electrodiagnostic, neurophysiologic, neuroimaging or clinically laboratory studies

- Disease duration of less than or equal to four years from symptom onset

- Age 30-80 years at time of disease onset

- Ability to provide informed consent

- Ability to comply with study procedures

- Medically safe to have lumbar puncture (lumbar puncture volunteers only)

Exclusion Criteria:

- Clinical evidence of chronic liver or renal failure

- Genetically confirmed diagnosis of hereditary spastic paraparesis or spinal motor atrophy (SMA) disease

- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)

- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)

3. Neurological Disease Mimic Volunteers

Inclusion Criteria:

Diagnosis of one of the following:

Pure Lower Motor Neuron Disease (LMND) mimics:

- Multi-focal motor neuropathy

- Autoimmune motor neuropathy

- Cervical or lumbosacral radiculopathies

Peripheral mononeuropathies:

- Ulnar neuropathy

- Carpal tunnel syndrome/median neuropathy

- Peroneal neuropathy

- Sciatic neuropathy

- Spinal muscular atrophy

- Spinobulbar muscular atrophy (Kennedy's disease)

- Charcot Marie-Tooth Disease (CMT)

Pure Upper Motor Neuron Disease (UMND) mimics:

- Cervical myelopathy

- Multiple sclerosis

- Hereditary spastic paraparesis

- Age 30-80 years

- Ability to provide informed consent

- Ability to comply with study procedures

- Medically safe to have lumbar puncture (lumbar puncture volunteers only)

Exclusion Criteria:

- Diagnosis of suspected, possible, probable or definite ALS either sporadic or familial

- Presence of positive family history of ALS

- Clinical evidence of chronic renal or liver failure

- Presence of a bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (lumbar puncture volunteers only)

- Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (lumbar puncture volunteers only)

4. Healthy Control Volunteers Inclusion Criteria

- Absence of a known neurological disorder.

- Age 30 - 80 years.

- Ability to provide informed consent.

- Ability to comply with study procedures.

- Medically safe to have lumbar puncture.

Exclusion Criteria:

- History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative disease.

- Presence of positive family history of ALS.

- Clinical evidence of chronic liver or renal failure.

- Presence of bleeding disorder, problems with CSF pressure, allergy to local anesthetics, or a topical or other skin infection at the LP site (LP research volunteers only).

- Research participant must not be taking anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin (LP research volunteers only).

Phoenix Neurological Associates, Ltd.

Phoenix, Arizona 85018
United States

University of California Irvine

Orange, California 92868
United States

Mayo Clinic Neurology

Jacksonville, Florida 32224
United States

University of Miami

Miami, Florida 33136
United States

Emory University

Atlanta, Georgia 30322
United States

University of Chicago

Chicago, Illinois 60637
United States

Johns Hopkins University

Baltimore, Maryland 21205
United States

Massachusetts General Hospital

Boston, Massachusetts 02129
United States

Lahey Clinic

Burlington, Massachusetts 01805
United States

Saint Mary's Healthcare

Grand Rapids, Michigan 49503
United States

Hennepin County Medical Center

Minneapolis, Minnesota 55404
United States

Saint Louis University

Saint Louis, Missouri 63104
United States

Washington University

Saint Louis, Missouri 63110
United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire 03756
United States

Robert Wood Johnson/UMDNJ

New Brunswick, New Jersey 08901
United States

Upstate Clinical Research, LLC

Albany, New York 12205
United States

Beth Israel Medical Center, PACC

New York, New York 10003
United States

SUNY Upstate Medical University

Syracuse, New York 13210
United States

Carolinas Health Care

Charlotte, North Carolina 28207
United States

Duke University Medical Center

Durham, North Carolina 27705
United States

Wake Forest University

Winston-Salem, North Carolina 27157
United States

OSU Medical Center

Columbus, Ohio 43210
United States

Providence ALS Clinic

Portland, Oregon 97213
United States

Oregon Health & Science University

Portland, Oregon 97233
United States

Pennsylvania State University

Hershey, Pennsylvania 17033
United States

Drexel University College of Medicine

Philadelphia, Pennsylvania 19107
United States

University of Pittsburgh

Pittsburgh, Pennsylvania 15213
United States

Methodist Neurological Institute

Houston, Texas 77030
United States

University of Utah

Salt Lake City, Utah 84132
United States

Montreal Neurological Institute

Montreal, Quebec H3A 2B4
Canada